Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

The association between the polymorphisms of TNF-α and non-Hodgkin lymphoma: a meta-analysis

Authors: Yong-Qiao He, Jin-Hong Zhu, Shao-Yi Huang, Zhuo Cui, Jing He, Wei-Hua Jia

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

Many genetic variations in the promoter region of tumor necrosis factor alpha (TNF-α) may confer host susceptibility to cancer by influencing TNF-α expression. Nevertheless, the results remain inconclusive. The current meta-analysis was performed to investigate the association between three common TNF-α promoter polymorphisms and the risk of non-Hodgkin lymphoma (NHL). A literature search was conducted mainly from PubMed for all eligible studies. The pooled odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) were used to assess the association of TNF-α polymorphisms with the risk of NHL. TNF-α −308 A allele showed a statistically significant increased risk for NHL under the homozygous (AA vs. GG, OR = 1.51, 95 % CI = 1.26–1.80) and recessive (OR = 1.47, 95 % CI = 1.23–1.75) models, respectively. The stratified analyses showed an increased risk of NHL with the presence of TNF-α −308 A allele among Africans and Caucasians, but a decreased risk among Asians. No association was observed between −238 G/A polymorphism and NHL risk either in the overall analysis or in the stratified analysis. Similarly, pooled analysis did not reveal an altered risk of NHL with −857 C/T polymorphism. Nonetheless, a statistically significant association was observed among Asians when stratified by ethnicity. Among the three genetic variations of interest, TNF-α −308 G/A polymorphism was significantly associated with the risk of NHL; neither −238 G/A nor −857 C/T polymorphism was shown to alter the overall NHL risk; however, stratified analysis by ethnicity observed a statistically significant association between −857 C/T polymorphism and the risk of NHL among Asians.
Literature
1.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.PubMed
2.
Fears SSDaT (1992) Non-Hodgkin’s lymphoma time trends: United States and international data.
3.
Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh JW, et al. The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer. 1999;35:627–33.PubMed
4.
K. N. Naresh VSCSS (2000) Distribution of various subtypes of non-Hodgkin’s lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO classifications.
5.
Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011;21:293–8.PubMed
6.
Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16:405–8.PubMed
7.
Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551–9.PubMedPubMedCentral
8.
van Leeuwen MT, Grulich AE, Webster AC, McCredie MR, Stewart JH, et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood. 2009;114:630–7.PubMed
9.
Balkwill F (2002) Tumor necrosis factor or tumor promoting factor?
10.
Ardizzoia A, Lissoni P, Brivio F, Tisi E, Perego MS, et al. Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents. 1992;6:103–7.PubMed
11.
Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol. 1997;15:499–508.PubMed
12.
Warzocha K, Salles G, Bienvenu J, Barbier Y, Bastion Y, et al. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas. Leukemia. 1997;11 Suppl 3:441–3.PubMed
13.
Li D, Li G, Wang B. Serum tumor necrosis factor-alpha levels in non-Hodgkin’s lymphoma patients and its relationship to prognosis. Zhonghua Zhong Liu Za Zhi. 1997;19:293–6.PubMed
14.
Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin’s lymphoma outcome. Blood. 1998;91:3574–81.PubMed
15.
Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94:3195–9.PubMedPubMedCentral
16.
Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens. 1998;51:605–12.PubMed
17.
Demeter J, Porzsolt F, Ramisch S, Schmid M, Messer G. Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in hairy cell leukaemia. Br J Haematol. 1997;97:132–4.PubMed
18.
Chouchane L, Ahmed SB, Baccouche S, Remadi S. Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer. 1997;80:1489–96.PubMed
19.
Demeter J, Porzsolt F, Ramisch S, Schmidt D, Schmid M, et al. Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br J Haematol. 1997;97:107–12.PubMed
20.
Fitzgibbon J, Grenzelias D, Matthews J, Lister TA, Gupta RK. Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma. Br J Haematol. 1999;107:388–91.PubMed
21.
Wihlborg C, Sjoberg J, Intaglietta M, Axdorph U, Pisa EK, et al. Tumour necrosis factor-alpha cytokine promoter gene polymorphism in Hodgkin’s disease and chronic lymphocytic leukaemia. Br J Haematol. 1999;104:346–9.PubMed
22.
Tsukasaki K, Miller CW, Kubota T, Takeuchi S, Fujimoto T, et al. Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Res. 2001;61:3770–4.PubMed
23.
Bogunia-Kubik K, Mazur G, Urbanowicz I, Wrobel T, Kuliczkowski K, et al. Lack of association between the TNF-alpha promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia. Int J Immunogenet. 2005;33:21–4.
24.
Hellmig S, Fischbach W, Goebeler-Kolve ME, Folsch UR, Hampe J, et al. A functional promotor polymorphism of TNF-alpha is associated with primary gastric B-Cell lymphoma. Am J Gastroenterol. 2005;100:2644–9.PubMed
25.
Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood. 2006;107:4101–8.PubMedPubMedCentral
26.
Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res. 2006;66:9771–80.PubMed
27.
Bel Hadj Jrad B, Chatti A, Laatiri A, Ahmed SB, Romdhane A, et al. Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin’s lymphomas. Eur J Haematol. 2007;78:117–22.PubMed
28.
Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin lymphoma study. Carcinogenesis. 2007;28:704–12.PubMed
29.
Cerhan JR, Liu-Mares W, Fredericksen ZS, Novak AJ, Cunningham JM, et al. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin’s lymphoma. Cancer Epidemiol Biomarkers Prev. 2008;17:3161–9.PubMedPubMedCentral
30.
Jevtovic-Stoimenov T, Kocic G, Pavlovic D, Macukanovic-Golubovic L, Marjanovic G, et al. Polymorphisms of tumor-necrosis factor-alpha −308 and lymphotoxin-alpha + 250: possible modulation of susceptibility to apoptosis in chronic lymphocytic leukemia and non-Hodgkin lymphoma mononuclear cells. Leuk Lymphoma. 2008;49:2163–9.PubMed
31.
Aissani B, Ogwaro KM, Shrestha S, Tang J, Breen EC, et al. The major histocompatibility complex conserved extended haplotype 8.1 in AIDS-related non-Hodgkin’s lymphoma. J Acquir Immune Defic Syndr. 2009;52:170–9.PubMedPubMedCentral
32.
Andrie E, Michos A, Kalampoki V, Pourtsidis A, Moschovi M, et al. Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol. 2009;83:334–42.PubMed
33.
Fernberg P, Chang ET, Duvefelt K, Hjalgrim H, Eloranta S, et al. Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control. 2010;21:759–69.PubMed
34.
Thunberg U, Enblad G, Turesson I, Berglund M. Genetic variation in tumor necrosis factor and risk of diffuse large B-cell lymphoma and follicular lymphoma: differences between subgroups in Swedish patients. Leuk Lymphoma. 2010;51:1563–6.PubMed
35.
Xiao H, Zhang K. Genetic polymorphisms of tumor necrosis factor-alpha and lymphotoxin-alpha in Chinese patients with non-Hodgkin lymphoma. Ann Hematol. 2010;90:725–7.PubMed
36.
Ibrahim A, Abdel Rahman H, Khorshied M, Sami R, Nasr N, et al. Tumor necrosis factor alpha−308 and lymphotoxin alpha + 252 genetic polymorphisms and the susceptibility to non-Hodgkin lymphoma in Egypt. Leuk Res. 2011;36:694–8.PubMed
37.
Bi X, Zheng T, Lan Q, Xu Z, Chen Y, et al. Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma. Am J Hematol. 2012;87:766–9.PubMedPubMedCentral
38.
Hosgood 3rd HD, Au WY, Kim HN, Liu J, Hu W, et al. IL10 and TNF variants and risk of non-Hodgkin lymphoma among three Asian populations. Int J Hematol. 2013;97:793–9.PubMedPubMedCentral
39.
Lech-Maranda E, Mlynarski W, Grzybowska-Izydorczyk O, Borowiec M, Pastorczak A, et al. Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia. Genes Chromosom Cancer. 2013;52:287–96.PubMed
40.
Liu J, Song B, Wang T, Liu Y, Hao J, et al. Genetic variations in CTLA-4, TNF-alpha, and LTA and susceptibility to T-cell lymphoma in a Chinese population. Cancer Epidemiol. 2013;37:930–4.PubMed
41.
Nasiri H, Farajnia S, Rezamand A, Movassaghpour AA, Esmaeili HA, et al. Genetic variations of tumor necrosis factor -alpha−308 and lymphotoxin-alpha + 252 in Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia Patients. Iran J Basic Med Sci. 2013;16:990–5.PubMedPubMedCentral
42.
Yri OE, Ekstrom PO, Hilden V, Gaudernack G, Liestol K, et al. Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Leuk Lymphoma. 2013;54:2205–14.PubMed
43.
Swartz MK. The PRISMA statement: a guideline for systematic reviews and meta-analyses. J Pediatr Health Care. 2011;25:1–2.PubMed
44.
Wang SS, Cozen W, Cerhan JR, Colt JS, Morton LM, et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res. 2007;67:5042–54.PubMed
45.
Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood. 2008;112:5150–60.PubMedPubMedCentral
46.
Abdou AM, Gao X, Cozen W, Cerhan JR, Rothman N, et al. Human leukocyte antigen (HLA) A1-B8-DR3 (8.1) haplotype, tumor necrosis factor (TNF) G-308A, and risk of non-Hodgkin lymphoma. Leukemia. 2010;24:1055–8.PubMedPubMedCentral
47.
Chen Y, Zheng T, Lan Q, Foss F, Kim C, et al. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood. 2011;117:585–90.PubMedPubMedCentral
48.
Mainou-Fowler T, Dickinson AM, Taylor PR, Mounter P, Jack F, et al. Tumour necrosis factor gene polymorphisms in lymphoproliferative disease. Leuk Lymphoma. 2000;38:547–52.PubMed
49.
Spink CF, Keen LJ, Mensah FK, Law GR, Bidwell JL, et al. Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol. 2006;133:293–300.PubMed
50.
Habermann TM, Wang SS, Maurer MJ, Morton LM, Lynch CF, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood. 2008;112:2694–702.PubMedPubMedCentral
51.
McAulay KA, Haque T, Crawford DH. Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer. 2009;101:1019–27.PubMedPubMedCentral
52.
Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7:27–38.PubMed
53.
Au WY, Fung A, Wong KF, Chan CH, Liang R. Tumor necrosis factor alpha promoter polymorphism and the risk of chronic lymphocytic leukemia and myeloma in the Chinese population. Leuk Lymphoma. 2006;47:2189–93.PubMed
54.
Babel N, Vergopoulos A, Trappe RU, Oertel S, Hammer MH, et al. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation. 2007;84:387–91.PubMed
55.
Takashiba S, Shapira L, Amar S, Van Dyke TE. Cloning and characterization of human TNFα promoter region. Gene. 1993;131:307–8.PubMed
56.
Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25:409–16.PubMed
57.
Ding B, Fu S, Wang M, Yue C, Wang W, et al. Tumor necrosis factor alpha −308 G>A polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer. 2012;22:213–9.PubMed
58.
Zhang HL, Zhang YJ. A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer. Tumour Biol. 2013;34:1659–65.PubMed
59.
Hong Y, Ge Z, Jing C, Shi J, Dong X, et al. Functional promoter −308G>A variant in tumor necrosis factor alpha gene is associated with risk and progression of gastric cancer in a Chinese population. PLoS ONE. 2013;8:e50856.PubMedPubMedCentral
60.
Fang F, Yao L, Yu XJ, Yu L, Wu Q. TNFalpha −308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10,184 cases and 12,911 controls. Breast Cancer Res Treat. 2010;122:267–71.PubMed
61.
Xie L, Liang XN, Deng Y, Qin X, Li S. TNF-alpha-308G/A polymorphisms and nasopharyngeal cancer risk: a meta-analysis. Eur Arch Otorhinolaryngol. 2013;270:1667–72.PubMed
62.
Azmy IA, Balasubramanian SP, Wilson AG, Stephenson TJ, Cox A, et al. Role of tumour necrosis factor gene polymorphisms (−308 and −238) in breast cancer susceptibility and severity. Breast Cancer Res. 2004;6:R395–400.PubMedPubMedCentral
63.
Gorouhi F, Islami F, Bahrami H, Kamangar F. Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer. 2008;98:1443–51.PubMedPubMedCentral
64.
Zhou P, Lv GQ, Wang JZ, Li CW, Du LF, et al. The TNF-alpha-238 polymorphism and cancer risk: a meta-analysis. PLoS ONE. 2011;6:e22092.PubMedPubMedCentral
65.
Yu JY, Li L, Ma H, Liu K, Cheng X, et al. Tumor necrosis factor-alpha 238 G/A polymorphism and gastric cancer risk: a meta-analysis. Tumour Biol. 2013;34:3859–63.PubMed
66.
Cheng K, Zhao YJ, Liu L, Wan JJ. Tumor necrosis factor-alpha 238 G/A polymorphism and risk of hepatocellular carcinoma: evidence from a meta-analysis. Asian Pac J Cancer Prev. 2013;14:3275–9.PubMed
67.
Cen G, Wu W. Association between tumor necrosis factor-alpha 857C/T polymorphism and gastric cancer: a meta-analysis. Tumour Biol. 2013;34:3383–8.PubMed
68.
Conde L, Halperin E, Akers NK, Brown KM, Smedby KE, et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010;42:661–4.PubMedPubMedCentral
69.
Smedby KE, Foo JN, Skibola CF, Darabi H, Conde L, et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet. 2011;7:e1001378.PubMedPubMedCentral
70.
Tan DE, Foo JN, Bei JX, Chang J, Peng R, et al. Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population. Nat Genet. 2013;45:804–7.PubMed
Metadata
Title
The association between the polymorphisms of TNF-α and non-Hodgkin lymphoma: a meta-analysis
Authors
Yong-Qiao He
Jin-Hong Zhu
Shao-Yi Huang
Zhuo Cui
Jing He
Wei-Hua Jia
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2569-6

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue

Research Article

miR149 rs71428439 polymorphism and risk of clear cell renal cell carcinoma: a case–control study

Research Article

ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer

Research Article

MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3

Research Article

Antitumor activities of ginseng polysaccharide in C57BL/6 mice with Lewis lung carcinoma

Research Article

Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy

Research Article

MicroRNA-191 promotes pancreatic cancer progression by targeting USP10
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits